<DOC>
	<DOCNO>NCT01265836</DOCNO>
	<brief_summary>The purpose study establish proportion patient lipid-lowering pharmacological treatment ( statin combination ) reach LDL-C goal accord updated 2004 National Cholesterol Education Program Adult Treatment Panel III ( NCEP ATP III ) guideline .</brief_summary>
	<brief_title>Dyslipidemia Treatment Thailand Cardiovascular Outcomes</brief_title>
	<detailed_description>MC MD</detailed_description>
	<mesh_term>Dyslipidemias</mesh_term>
	<criteria>Provision subject inform consent , Female male age = 18 year Patients eligible treatment dyslipidemia statin , accord current guideline NCEP ATPIII Dyslipidemias Atherosclerosis Prevention Receiving lipidlowering drug treatment least 15 day . Involvement plan conduct study ( applies either AstraZeneca staff staff study site ) . Previous enrolment randomisation treatment present study Participation clinical study last 90 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Dyslipidemia Treatment Cardiovascular Outcomes</keyword>
</DOC>